


GRANTED**(IN495022)**

Formulation for wound healing



NEED

Each year, over 300 million chronic wounds worldwide fail to heal properly, leading to 85% of lower limb amputations. Current dressings often lack biocompatibility, causing delayed healing, infection risks, and healthcare costs rising above \$25B globally.

TECHNOLOGY OVERVIEW

This invention presents a porous scaffold composition combining chitosan and chondroitin sulfate. It forms in-situ, promoting faster wound healing by mimicking natural tissue environments, enhancing cell attachment, and minimizing infection without relying on synthetic chemical processes or external scaffold fabrication.

TECHNOLOGY KEY FEATURES

In-situ forming biopolymer scaffold with high molecular weight chitosan and chondroitin sulfate, supporting rapid wound healing, infection control, and natural tissue regeneration without complex synthetic steps or toxic additives.

[Read more here](#)

MARKET ANALYSIS

The global wound care market is projected to reach \$31.7 billion by 2033, growing at a CAGR of 5.2%. Aging population, diabetes prevalence, and demand for advanced bioactive wound therapies are driving growth. [Source: Market Research Future, 2024]

Target Industries

Advanced Wound Care, Regenerative Medicine, Hospital and Home Healthcare. , Wound dressing product developers, regenerative therapy research units, clinical healthcare solution providers for acute and chronic wound management.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913